Navigation Links
Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
Date:6/27/2011

ot yet developed metastatic disease.

In the '147 trial, adverse events and serious adverse events were relatively similar between the XGEVA and placebo arms. Hypocalcemia and osteonecrosis of the jaw (ONJ) were reported with increased frequencies in the XGEVA treated patients. The yearly rate of ONJ in the XGEVA arm was similar to prior XGEVA trial results. Back pain was the most common adverse event reported in the XGEVA arm of the trial.

About XGEVA

XGEVA is the first and only RANK Ligand inhibitor approved by the FDA indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. XGEVA was approved following a six month priority review by the FDA.  XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma. XGEVA is the first novel bone metastases treatment for advanced cancer patients in nearly a decade. Delivered as an every four week 120 mg subcutaneous injection, XGEVA provides a unique option for urologists and oncologists to prevent SREs in patients with advanced cancer.

XGEVA is a fully human monoclonal antibody that binds to RANK Ligand, a protein essential for the formation, function and survival of osteoclasts (the cells that break down bone). XGEVA prevents RANK Ligand from activating its receptor, RANK, on the surface of osteoclasts, thereby decreasing bone destruction.

XGEVA has been studied in over 7,000 patients with cancer. In clinical trials, XGEVA demonstrated a clinically meaningful improvement compared to the previous standard of care in preventing bone complications. XGEVA is also being investigated for the potential use to delay the onset of bone metastasis in adjuvant breast cancer.

XGEVA Skeletal-Related Events Regulatory Status

XGEVA is currently approved in the U.S. for the prevention of SREs in patients with bone metastases from solid tumors.  XGEVA was approved following a
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... development of botanical and plant-derived compounds. BCC Research reveals in its new ... 2020 because this market defines the category and generates the most market demand. ...
(Date:9/2/2015)... Sept. 2, 2015 Veracyte, Inc. (NASDAQ: ... , president and chief executive officer, will present at ... 16, 2015 at 10:30 a.m. ET in ... live audio webcast and subsequent replay may be accessed ... be available shortly after conclusion of the presentation and ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... critical demand to aid high-risk surgeries. From vital sign monitoring in ICU to ... Intel technology enables surgeon to make real-time clinical decisions with simultaneous access to ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3
...  Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global ... sale of enzyme and protein products for the industrial ... will launch FibreZyme® G5000, a next generation, ... to improve paper quality and improve the economics of ...
... awareness about the disease and its overall occurrence and ... (MS) market. This is being exacerbated by the limited ... immediate need for innovative and enhanced therapeutic and diagnostic ... of treatment options. New analysis from Frost ...
... 2012   Kimberly-Clark Corporation (NYSE: KMB ... vice president of Global Nonwovens, has been named to ... in Corporate America." The Top 100 listing showcases ... and executives representing a diverse range of industries who ...
Cached Biology Technology:Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference 2Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference 3European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan 2European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan 3Kimberly-Clark's Bob Stargel Named One of Savoy Magazine's Top 100 Most Influential Blacks in Corporate America 2Kimberly-Clark's Bob Stargel Named One of Savoy Magazine's Top 100 Most Influential Blacks in Corporate America 3
(Date:8/6/2015)... and TELTOW, Germany , August ... Siggraph Conference, SensoMotoric Instruments (SMI) shows the ... , based on Epson,s Moverio BT-200 see-through ... platform. With this new solution, unprecedented quality and efficiency ... interaction with context-sensitive displays. For the first time, professionals ...
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... Kina, 31. juli 2015 Den 10. internationale ... af BGI fra den 22. - 25. oktober i ... fejrer sin 10-års fødselsdag i år. Siden starten i ... årlige møder på ,omik,-feltet, og er en af de ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... (Rockville, MD September 20, 2007) Fifteen students mentored ... (ASPB) were selected to receive the 2007ASPB Summer Undergraduate ... to devote full-time effort to his or her research ... award also includes $500 to the mentor for lab ...
... West Nile virus first struck New York City in ... and public health officials alike, showing that even affluent, ... Nile virus has been widely studied, there is still ... differs between urban and rural areas. Assistant professor ...
... anniversaries of Annals of the Entomological Society of America ... oldest journals. The occasion will be celebrated at ESAs ... over 2,000 entomologists will gather for four days of ... were launched the same year (1908), but with very ...
Cached Biology News:ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 3UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC 2ESA celebrates 100 years of insect science journals 2
Glutamate Receptor 5/1a...
Dual Color Mouse anti-Human Anti-Kappa FITC/CD19 PE Class: Antibody Product Group: Immunogluobulin...
... monoclonal [EP282Y] to Asparagine synthetase ... tested applications). ... to residues in the C-terminus ... Entrez GeneID: ...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Biology Products: